TY  - GEN
AU  - Scagliotti,Giorgio V
AU  - Gaafar,Rabab
AU  - Nowak,Anna K
AU  - Nakano,Takashi
AU  - van Meerbeeck,Jan
AU  - Popat,Sanjay
AU  - Vogelzang,Nicholas J
AU  - Grosso,Federica
AU  - Aboelhassan,Rasha
AU  - Jakopovic,Marko
AU  - Ceresoli,Giovanni L
AU  - Taylor,Paul
AU  - Orlandi,Francisco
AU  - Fennell,Dean A
AU  - Novello,Silvia
AU  - Scherpereel,Arnaud
AU  - Kuribayashi,Kozo
AU  - Cedres,Susana
AU  - Sørensen,Jens Benn
AU  - Pavlakis,Nick
AU  - Reck,Martin
AU  - Velema,Derek
AU  - von Wangenheim,Ute
AU  - Kim,Miyoung
AU  - Barrueco,José
AU  - Tsao,Anne S
TI  - Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial
SN  - 2213-2619
PY  - 2020///0422
KW  - Aged
KW  - Antineoplastic Agents
KW  - administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Cisplatin
KW  - Double-Blind Method
KW  - Female
KW  - Humans
KW  - Indoles
KW  - Lung Neoplasms
KW  - drug therapy
KW  - Male
KW  - Mesothelioma
KW  - Mesothelioma, Malignant
KW  - Middle Aged
KW  - Pemetrexed
KW  - Pleural Neoplasms
KW  - Progression-Free Survival
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/S2213-2600(19)30139-0
ER  -